TITLE

Deep in the Heart of Texas Bio--a Takeover?

AUTHOR(S)
Leibs, Anthony
PUB. DATE
May 1999
SOURCE
Mergers & Acquisitions Report;05/24/99, Vol. 12 Issue 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses the need of Houston, Texas-based Texas Biotechnology Corp. (TBC) to make an alliance with commercially experienced corporate partner. Business and financial information on TBC; Comments from some industry analysts; Significance of the approval of Novastan, an anti-coagulant drugs produced by TBC, by the United States Food and Drug Administration for the company.
ACCESSION #
1901804

 

Related Articles

  • LI summit update: Expand LI involvement in international commerce. Crosson, Matthew // Long Island Business News (7/1993 to 5/2009);5/15/95, Vol. 42 Issue 20, p16 

    Reports on a trade show program launched by the New Long Island Partnership in 1995. Program's focus on biotechnology industry; Participation in the Bio International Conference and Exhibition; Value of exports from Long Island.

  • The effects of alliance portfolio characteristics and absorptive capacity on performance A study of biotechnology firms. George, Gerard; Zahra, Shaker A.; Wheatley, Kathleen K.; Khan, Raihan // Journal of High Technology Management Research;Autumn2001, Vol. 12 Issue 2, p205 

    In many high technology industries, strategic alliances have become important for improving a firm's financial performance by providing knowledge that can be used to develop the capabilities needed to introduce new products. Therefore, researchers have examined those characteristics of alliances...

  • Alliances/Collaborations. Holland-Moritz, Pam // Drug Discovery & Development;Jun2003, Vol. 6 Issue 6, p22 

    Reports on alliances and collaborations formed between biotechnology companies involved in drug development. Intronn Inc. and ProBioGen AG; Applied BioPhysics Inc.'s collaborative research with George Plopper at Rensselaer Polytechnic Institute in Troy, New York; Co-marketing agreement between...

  • Big pharma.  // New Internationalist;Sep2002, Issue 349, p19 

    Reports on the formation of alliances by biotechnology companies with the pharmaceutical giants. Profit forecast for gene therapy; Ratio of biotechnology companies manufacturing medicines in 2000; Global sales of plant-based drugs in 1999.

  • Pharma-biotech research alliances increase. Liebman, Milton // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p18 

    Focuses on the alliances formed between pharmaceutical companies and biotechnology firms in the U.S. Increase funding for drug development; Expansion of research on cancer and diabetes drugs; Impact of the move on the biotechnology sector.

  • Becoming Partners of Choice. Richardson, Jason; Evangelista, Elio // Pharmaceutical Executive;Nov2002 Supplement, Vol. 22, p12 

    Discusses the pharmaceutical-biotechnology alliances in the U.S. Potential gains and pitfalls of the alliances; Method for maximizing pharma-biotech alliances; Strategies and tactics used by companies to approach pharma-biotech alliances. INSETS: Fruits of Alliance Labors;Pfizer's Partnership...

  • Hope for the Best Prepare for the Worst. Fiscus, Philip W. // Pharmaceutical Executive;Nov2002 Supplement, Vol. 22, p22 

    Explores the alliances between pharmaceutical industry and biotechnology industry in the U.S. Inherent risks in the alliances; Importance of business recovery plans in pharma-biotech alliances; Compliance of the biotech companies to clinical regulatory standards; Examination of a biotech...

  • Biotechnology --- A Challenge for the Modern Contract Manufacturer. Lambert, Rolf // Pharmaceutical Technology Europe;Mar2003 Supplement, Vol. 15, p31 

    Discusses ways to achieve the synergistic cooperation between European contract manufacturing organizations (CMO) and biotechnology firms. Reasons for outsourcing; Services offered by a CMO; Attributes of a good CMO; Gap between the cultures and business methods of biotechnology firms and...

  • Becoming a Partner of Choice and Evaluating Prospective Alliances. Wallis, David; Heybroek, Jan // Pharmaceutical Technology Europe;Aug2003 Supplement, Vol. 15, p18 

    Discusses the concept of alliance in the pharmaceutical and biotechnology industries. Procedure for determining strategic partnering objectives; Importance of assessing a potential partner's capabilities and ability to meet its own strategic needs; Background on due diligence. INSETS: Managing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics